Forensic Analysis · Pharmaceuticals & Biotechnology · as of Nov 9, 2026
Impact Biomedical Inc. (IBO)
A forensic read on Impact Biomedical Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Distress
Financial health
-4.0
Distress distance
3
Forensic signals
-140.4%
ROE
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Impact Biomedical Inc. earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads -4.0, placing it in the Distress zone. 3 forensic signals were flagged in its latest SEC filings, led by accruals ratio (% of NOA).
What the filings flag
+91.3%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +91.3% relative to their own average in FY2025 — scaled by NOA itself, not by total assets, which is what the Forensic Screens card's own accrual row divides by. Accruals are building sharply — a large slice of profit sits in operating assets, not cash. An accrual is a claim that still has to be collected or written down, so the gap resolves in a later period whichever way it goes. Net operating assets also rose $820,000 through acquisitions (shares issued for businesses); that purchase is investing and is excluded from this ratio. A cash-flow measure on the same base disagrees: reported earnings ran behind operating cash by 96% of net operating assets, against an accruals ratio of 91.3%. The two are computed differently: the accruals ratio is the change in net operating assets over average net operating assets, while the cash-flow figure is net income less operating cash flow over that same average. Read them as two results, not one.Accruals ratio: the year-over-year change in net operating assets, relative to their own average.NOA (net operating assets): the money tied up in running the business, operating assets minus operating liabilities.
41% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 41% of revenue in FY2025 — about $0.00 per basic share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the basic count still rose about 193.3% a year across FY2024–FY2025, above the level at which the count is a material claim on a stake, and only one year's change is on file — enough to state what a holder gave up, not enough to say whether the rate is climbing or coming down. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
$25M
FY2024
Goodwill impairments.Took $25M of goodwill writedowns across 1 year (FY2024 ($25M)). Writedowns mean past acquisitions underperformed what was paid for them.
Key fundamentals
Latest Revenue$32,000
Net Margin-36993.8%
Return on Equity-140.4%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Impact Biomedical Inc.'s actual 10-K/10-Q/8-K filings?